About CTCBIO
CTCBIO is a publicly listed company based in Seoul (South Korea) founded in 1993. Manufacturer of pharmaceuticals, veterinary drugs and animal feed supplements. The company has 257 employees. CTCBIO offers products and services including Bio Products and Research Services. Its focus areas include Traditional Pharmaceuticals, Generics and Diversified. Its legal entity is Citi C Bio Inc.
Company details
CTCBIO is a manufacturer of pharmaceuticals, veterinary drugs, animal feed supplements and functional foods. It pharmaceuticals include anticancer agents, antibiotics, bone injury treatments, antiulcer agents, blood flow stimulants and others. Its veterinary drugs include vaccines, antibiotics, immune enhancers, enzymes, organic acid, avian influenza-related agents and others. Its animal feed supplements include pigments, kapok seed meal, sesame meal and others. Its functional food business includes the development and manufacture of enzymes, lactobacillus and related products mainly used in dairy products. It also involves in the development of pharmaceutical manufacturing technology and know-how. The Company distributes its products within domestic market and to overseas markets.
- Headquarters Seoul, South Korea
- Employees 257
- Stage Public
- SectorsHealthcare
- Email••••••••
- Website ctcbio.com
- Social LinkedIn
- Legal Name Ctc Bio Inc.
- Annual Revenue$85.7 M (USD)3.25as on Dec 31, 2025
- Net Profit$2.24 M (USD)as on Dec 31, 2025
- EBITDA$8.85 M (USD)1348.1as on Dec 31, 2025
- Employee Count257
Products & Services of CTCBIO
CTCBIO offers a comprehensive portfolio of products and services, including Bio Products and Research Services.
Bio products are developed and supplied for health and industrial uses
Research services are offered for bio innovation and equipment support
IPO & Listings of CTCBIO
CTCBIO is a publicly listed company on the KRX with ticker symbol 060590 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date21 Feb 2002
- Listed onKRX: 60590
- Listed entityCTC Bio Inc.
- Exchange sectorHealth technology
- ISINKR7060590007
- Share price2,920.00 KRW (+1.39% on the day) · 2026-10-14
- Market capitalisation68,857,272,949.00 KRW
- Price to earnings9.3
- EPS (diluted, trailing year)314.24 KRW
- Volume (last session)31,059
Financials of CTCBIO
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 123.77B KRW | 3.24B KRW | 12.78B KRW |
| 2024 | 119.88B KRW | -5.22B KRW | 882.5M KRW |
| 2023 | 137.88B KRW | -15.59B KRW | 1.37B KRW |
| 2022 | 165.21B KRW | 4.70B KRW | 17.94B KRW |
| 2021 | 140.32B KRW | -7.32B KRW | 3.34B KRW |
Detailed financial statements for CTCBIO
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Web traffic of CTCBIO
The website of CTCBIO (ctcbio.com) receives about 5.1K visits a month.
- Monthly visits5.1K
▲ 39.5% vs previous month
Websites whose visitors overlap most with CTCBIO. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
dailypharm.com | dailypharm.com | 100% | #33,384 | – | |
| medigatenews.com | 100% | #143,063 | View details | ||
| hitnews.co.kr | 100% | #146,502 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about CTCBIO
CTCBIO was founded in 1993.
CTCBIO is headquartered in Seoul, South Korea.
CTCBIO has 257 employees.
Annual revenue of CTCBIO is $85.7M as on Dec 31, 2025.
CTCBIO is a manufacturer of pharmaceuticals, veterinary drugs, animal feed supplements and functional foods. It pharmaceuticals include anticancer agents, antibiotics, bone injury treatments, antiulcer agents, blood flow stimulants and others. Its veterinary drugs include vaccines, antibiotics, immune enhancers, enzymes, organic acid, avian influenza-related agents and others. Its animal feed supplements include pigments, kapok seed meal, sesame meal and others. Its functional food business includes the development and manufacture of enzymes, lactobacillus and related products mainly used in dairy products. It also involves in the development of pharmaceutical manufacturing technology and know-how. The Company distributes its products within domestic market and to overseas markets.
CTCBIO offers Bio Products and Research Services.
Yes, CTCBIO is publicly traded on KRX under the ticker symbol 060590.
CTCBIO operates through Citi C Bio Inc..